Hematopoietic stem cell transplantation for solid tumors

Following success in the treatment of hematological malignancies, allogeneic hematopoietic stem cell transplantation (allo-HCT) has been used experimentally over the past decade to treat metastatic solid tumors such as renal cell carcinoma and breast cancer. This review discusses the rationale for allo-HCT for this indication, focusing on the recent clinical trials in the field as well as important historic clinical and laboratory data.